PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW

Abstract

Procedure for the generation of a reflex tear secretion, which comprises the chemical stimulation of the cornea of the eye of a subject by applying a controlled jet of a gas with a high CO.sub.2 content, of at least 80% of CO.sub.2. Compact device (1,1′) for the generation of a reflex tear secretion, comprising a gas source (7) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO.sub.2; and a pneumatic circuit connecting an outlet mouth of said gas source (7) with a gas outlet nozzle (3) of the device (1,1′), the circuit comprising pressure regulation means (8) and flow rate (17) regulation means suitable for ejecting puffs of gas through the outlet nozzle (3) at a predetermined pressure and flow rates.

Claims

1. Procedure for the generation of a reflex tear secretion, characterized in that it comprises chemical stimulation of the cornea of the eye of a subject by applying to the said cornea a controlled jet of a gas mixture with a high CO.sub.2 content, of at least the 80% CO.sub.2, in order to produce a transient decrease in pH of the tear film that covers the cornea, due to the immediate formation of carbonic acid resulting of the interaction in the tear of the CO.sub.2 with the H.sub.2O of the tear, which leads to the release of protons that stimulate the nerve endings of the polymodal nociceptors of the corneal surface, this chemical stimulation, combined with the mechanical and cold stimulation evoked by the gas jet, leading to a maximal reflex tear secretion, whose magnitude can be measured by conventional techniques for tear flow measurement used in Ophthalmology and Optometry for the diagnosis of tear secretion disturbances, especially for dry eye disease.

2. Procedure for the generation of a reflex tear secretion according to claim 1, characterized in that the outlet pressure of the jet of gas applied towards the corneal surface is higher than the atmospheric pressure.

3. Procedure for the generation of a reflex tear secretion according to claim 1, characterized in that the content of the gas used comprises a percentage of approximately 99% of CO.sub.2.

4. Procedure for the generation of a reflex tear secretion according to claim 1, characterized in that the jet of gas is applied towards the corneal surface with a flow rate equal to or greater than 150 ml/minute, preferably 200 ml/minute.

5. Procedure for the generation of a reflex tear secretion according to claim 1, characterized in that the jet of gas is a puff of a short duration applied in the direction of the corneal surface for a preset time comprised between 2 and 6 seconds, preferably 4 seconds.

6. Procedure for the generation of a reflex tear secretion according to claim 1, characterized in that the jet or puff of gas is applied to the corneal surface maintaining a separation distance equal to or greater than 1 mm, preferably 10 mm.

7. Compact device for the generation of a reflex tear secretion, characterized in that it comprises a gas source in the form of a disposable-type cartridge containing a pressurized gas with a composition of at least 80% of CO.sub.2; and a pneumatic circuit connecting an outlet mouth of said gas source with a gas outlet nozzle of the device, the circuit comprising pressure regulation means and flow rate regulation means suitable for ejecting puffs of the gas through the outlet nozzle at a predetermined pressure and flow rates, between 1 and 1.5 bar and at least 150 ml/minute, respectively, the gas source and the pneumatic circuit being assembled in a casing that can be grasped with one hand or can be attached to the instrument holding bar of a common ophthalmic examination table, and the device also comprises a user-operable gas puff trigger and a spacer bracket with a proximal end, coupled to the housing around the outlet nozzle, and a distal end, provided with a peripheral edge ergonomically configured to be supported on the target eye socket of a subject while firing the device, to provide an separation distance between the gas outlet nozzle and the corneal surface of the subject.

8. Compact device according to the claim 7, characterized in that the pressure regulation means are tightly connected to the outlet of the gas source and configured to regulate the pressure of the gas flow at the outlet of the gas source to a pre-established set point, between 1.2 and 1.6 bar, to provide a predetermined pressure at the outlet of the nozzle of approximately between 1.0 and 1.5, preferably 1.25 bar.

9. Compact device according to claim 7, characterized in that the pneumatic circuit also comprises electrovalve means arranged downstream of the pressure regulation means, configured to control the passage of the gas flow towards the outlet nozzle, the flow rate regulation means being arranged downstream of the solenoid valve means and connected to said outlet nozzle.

10. Compact device according to claim 7, characterized in that the pneumatic circuit further comprises pressure sensor means configured to measure pressure at one or more intermediate points along the gas flow path.

11. Compact device according to claim 10, characterized in that the pressure sensor means of the gas flow comprise a first pressure sensor designed to measure the intermediate pressure existing at the outlet of the pressure regulation means; and a second pressure sensor designed to measure the intermediate pressure existing at the entrance to the flow rate regulation means.

12. Compact device according to claim 10, characterized in that the pneumatic circuit also comprises safety valve means configured to ensure the evacuation of the flow of gas when the pressure detected by the pressure sensor means is higher than the set pressure value at the respective intermediate measurement points.

13. Compact device according to claim 7, characterized in that the pneumatic circuit also comprises filtering means of solid particles arranged in one or several intermediate points along the gas flow path.

14. Compact device according to claim 7, characterized in that it comprises electrical supply means.

15. Compact device according to claim 14, characterized in that the electrical supply means are configured by an electric battery rechargeable by means of an external charger connected to the electrical supply network.

16. Compact device according to claim 7, characterized in that it also comprises light and/or acoustic indicator means linked to different status and alarm situations of the device, such as the on or off status, activation of the trigger phase, pressure status alarm, load level of the electrical power supply means, among others.

17. Compact device according to claim 14, characterized in that it comprises control means governed by a microprocessor provided of a suitable software, configured to process the signals detected by the pressure sensors, during an activated trigger phase, and the signal of the state of charge of the electrical supply means, with the purpose of sending an actuation signal to the means of solenoid valve to project through the nozzle a controlled puff of gas, that is, with pre-established conditions of outlet pressure and flow for a predetermined time applied in the direction of the cornea of a subject.

18. Compact device according to claim 1, characterized in that the microprocessor is equipped with a personal area communications (PAN), allowing its connection with an external device able to perform reading/writing actions through an interface/application to obtain information associated to identification of cartridges using a NFC technology.

19. Compact device according to claim 7, characterized in that the spacer bracket is asymmetric and is rotatable around the outlet nozzle to be able to be used interchangeably in one eye or the other of the subject.

20. Compact device according to claim 7, characterized in that the peripheral edge of the spacer bracket intended to come into contact with the eye socket is covered by a protective element made of a biocompatible material, such as silicone, with antibacterial and hypoallergenic properties for greater hygiene and comfort.

21. Compact device according to claim 20, characterized in that said protective element is provided with removable fastening means, such as an adhesive, on the contact face with the spacer bracket to facilitate its placement and removal, being said protective element disposable and of single-use for each subject.

22. Compact device according to claim 7, characterized in that it is shaped in dimensions such as to make it portable and grasp with one hand, in the form of a pistol or similar, in where the casing is provided with a handle-like portion and a main body at the front end of which is the outlet nozzle of the CO.sub.2 puffs, and the trigger being integrated in an area of the housing.

23. Compact device according to claim 22, characterized in that the trigger is made up of a trigger positioned at an ergonomic distance from the handle capable of being actuated by at least a finger of the same hand that holds the grip.

24. Compact device according to claim 22, characterized in that the casing comprises a removable portion located in the area of the handle, provided with an internal cavity for the placement of a CO.sub.2 cartridge.

25. Compact device according to claim 7, characterized in that it is shaped to be coupled to the instrument holding bar of a common ophthalmological examination table, and in wherein the trigger comprises remote actuation means separate from the casing.

26. Kit for carrying out a measurement analysis of the tear flow magnitude, comprising a compact device according to claim 7, and a set of measurement strips for carrying out the Schirmer test, intended for the diagnosis of ophthalmic diseases, especially for dry eye disease, said measuring strip being especially suitable to be used to measure the magnitude of the maximum reflex tear secretion generated by the device, characterized in that the measurement strip is made up of a strip of millimeter filter paper with a length greater than 30 mm, the proximal end of which is intended to be inserted into the space between the bulbar conjunctiva and the eyelid as a tab with rounded edges to eliminate sharp angles and thus avoid irritation; and in that the filter paper strip is sterilized and the tab contains a dried solution of an ocular anesthetic.

27. Kit according to claim 26, characterized in that the filter paper strip has a width of approximately between 5 and 10 mm and a total length of approximately 50 mm.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0048] The attached drawings illustrate, by way of non-limiting example, two preferred embodiments of the device for producing reflex tear secretion, object of the invention. In these drawings:

[0049] FIG. 1 is a perspective view of a portable handheld compact device, according to a first preferred embodiment of the invention;

[0050] FIG. 2 is a side elevation view of the device of FIG. 1;

[0051] FIG. 3 is a front elevation view of the device of FIG. 1;

[0052] FIG. 4 is a top plan view of the device of FIG. 1;

[0053] FIG. 5 is a longitudinal section view of the device of FIG. 1, showing the internal components;

[0054] FIG. 6 is an enlarged view of FIG. 5, showing the connection of the tubes of the CO.sub.2 flow circuit;

[0055] FIG. 7 is a block diagram of the main components of the device according to the first embodiment of the invention;

[0056] FIGS. 8 and 9 are two perspective views of a device of essentially horizontal configuration, according to a second preferred embodiment of the invention, attachable to the instrument holding bar on a conventional ophthalmic examination table;

[0057] FIG. 10 is a schematic view of a Schirmer test strip especially suitable for measuring the amount of tear flow secreted by the device of the present invention;

[0058] FIG. 11 is a graph showing the tear secretion values before and after stimulation with CO.sub.2 in the group of healthy subjects;

[0059] FIG. 12 is a graph showing the differences in CO.sub.2 stimulated tear secretion values exhibited by normal and strong responders to CO.sub.2 in the group of healthy subjects;

[0060] FIG. 13 differences in STR within the population of healthy subjects

[0061] FIG. 14 is a graph showing the effect of CO.sub.2 stimulation with the CO.sub.2 stimulation device in subclinical patients;

[0062] FIG. 15 shows the response curve to CO.sub.2 stimulation in the group of Sjögren syndrome patients; and

[0063] FIG. 16 compares the mean values of BTR (black) and STR (gray) in the groups of healthy subjects, subclinical DED patients and SS patients.

DETAILED EXPLANATION OF THE INVENTION

[0064] A first preferred embodiment of a device according of the invention for the generation of a reflex tear secretion by means of a chemical stimulation of the corneal surface, is shown in FIGS. 1 to 6 which illustrate a portable handheld device 1 configured as a pistol.

[0065] The device 1 comprises a gas source 7 in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 99% CO.sub.2; and a pneumatic circuit that connects an outlet mouth of said gas source 7 with a gas outlet nozzle 3 of the device 1. The circuit comprises pressure regulating means 8 and flow rate 17 regulation means suitable for ejecting gas puffs through the nozzle outlet 3 at a predetermined pressure and flow rates. The gas source 7 and the pneumatic circuit are assembled in a casing 2. The device 1 further comprises a trigger 4 of the CO.sub.2 puff operable by a user.

[0066] In this first embodiment, the device 1 is shaped in dimensions such as to make it portable and graspable with one hand, in the form of a pistol, in which the housing 2 is provided with a handle-like portion 2a and a main body 2b at the front end of which is the outlet nozzle 3 for the CO.sub.2 puffs. Furthermore, the trigger is formed in this example by a trigger 4, which is positioned at an ergonomic distance from the handle 2a in order to be easily actuated by at least one finger of the same hand that holds the handle 2a.

[0067] The pressure regulating means 8 are tightly connected to the outlet mouth of the gas source 7 and configured to regulate the pressure of the CO.sub.2 flow at the outlet of the gas source 7 to a pre-established set point, preferably equal to or greater than 1.2 bar, calculated to provide a predetermined pressure at the outlet of the nozzle 3 of approximately atmospheric pressure.

[0068] The amount of CO.sub.2 diffused into the air is determined by the CO.sub.2 flow rate and the opening time of the gas outlet in each test. The CO.sub.2 flow rate is regulated to a fixed value and cannot be modified by the user. The opening time of the CO.sub.2 outlet is preset in the device programming and cannot be modified by the user. Depending on the selection of components and the regulation of the device, the CO.sub.2 flow at the outlet of nozzle 3 will be adjustable (at the factory) to a value greater than 50 ml/minute, under ambient conditions (1 bar pressure and 25° C. temperature). In this application example, a flow rate of 200 ml/minute applied for 4 seconds is expected.

[0069] The CO.sub.2 concentration on the surface of the eye is determined by the distance between the point of diffusion of the CO.sub.2 puff through the outlet nozzle 3 and the surface of the eye, as well as by the degree of dilution of CO.sub.2 in the atmospheric air during its trajectory to the eye.

[0070] For this, the device 1 comprises a spacer bracket 5 with a proximal end coupled to the housing 2 around the outlet nozzle 3 and a distal end provided with a peripheral edge ergonomically configured to be supported on the socket of a target eye of a subject during the activation of the device 1 to provide an optimum separation distance between the gas outlet nozzle 3 and the corneal surface of the subject. In this example, the separation distance is 10 mm, although it could vary depending on the set flow and pressure parameters of the CO.sub.2 puff at the outlet nozzle 3. The minimum distance is 1 mm as long as it is used properly, in conjunction with suitable positioning systems.

[0071] According to this example, said spacer bracket 5 is asymmetrical and rotatable around the outlet nozzle 3 to be able to carry out the test indistinctly in one eye or the other of the patient. The peripheral edge intended to come into contact with the eye socket is covered by a protective element 6 to improve comfort, and which is easily replaceable for its replacement for each new patient. In this example, the protective element 6 is made of a non-woven fabric made of biocompatible silicone with antibacterial and hypoallergenic properties for greater hygiene and comfort. In addition, it includes a removable adhesive on the face in contact with the spacer bracket 5 to facilitate its removal, being disposable and for single use for each patient.

[0072] In the example, a spacer bracket 5 with open walls is shown to allow inspection of the eye during the test. However, a spacer bracket made of a closed-walled body in a transparent material could be used to avoid dispersion of CO.sub.2 while allowing visualization of the eye.

[0073] Therefore, the device 1 of the invention is configured to provide a controlled pulse or breath of a gas, with a high content of CO.sub.2, which ensures the stimulation of all polymodal nociceptor corneal nerves, starting from 80% CO.sub.2, and preferably 99% CO.sub.2, with a constant flow rate for a preset time, and maintaining a preset safety distance from the corneal surface, all with the purpose of creating a decrease in pH in the tear film that covers the cornea due to the formation immediate release of carbonic acid due to the interaction of CO.sub.2 with H.sub.2O in the tear, which causes the formation of H+protons that stimulate polymodal nociceptor nerve endings on the corneal surface. This stimulation is perceived in the brain of the patient as a moderate sensation of irritation while activating in the midbrain the nerve centers that mediate reflex tear secretion, the volume of which can be measured with conventional techniques used in the diagnosis of eye diseases specially for dry eye disease.

[0074] In this way, the user will perform a test on each patient that consists of applying at least one shot of a CO.sub.2 puff to one or both eyes.

[0075] It should be noted that the device of the invention does not provide the user with any type of test result. The result of the test will be evaluated by the user based on the change in the flow of tear secretion experienced by the patient and preferably measured with a Schirmer strip especially suitable to be used in combination with the device of the invention, as will be explained further ahead. Therefore, the device 1 does not perform test evaluation or diagnosis.

[0076] Next, the electronic components of the device 1 are described, referring to FIGS. 5 and 6, and especially to FIG. 7 which shows the block diagram of the main components thereof.

[0077] The device 1, according to the first preferred embodiment of the invention, comprises the following components: [0078] Gas source 7: [0079] The gas supply source is a disposable CO.sub.2 cartridge 7 (non-refillable). Each CO.sub.2 cartridge can be used for more than one test, even with more than one patient. In this example, a medical grade CO.sub.2-containing steel cartridge is used that contains (at full load) approximately 12 g of CO.sub.2 stored at a pressure of approximately 50 bar. The cartridge is provided of an identification system that prevents the use of the device with unauthorized cartridges. [0080] Pressure regulation means 8. [0081] In this example, a gas pressure regulator is used that has an inlet port for a ⅜″ threaded CO.sub.2 cartridge. It allows regulating the gas outlet pressure of cartridge 7 to the working pressure (set pressure) of the device 1 subsequently blocking the regulation setting. This regulation of the working pressure will be carried out in manufacturing and should not be manipulated by the user. [0082] Inlet safety valve 9. [0083] Mechanical pressure relief valve. Protects the circuit from accidental pressures higher than the pressure set on the pressure regulator. The CO.sub.2 is released to the outside through an opening in the housing 2 of the device 1. The valve 9 is regulated by means of a spring set at the adequate pressure. Once the pressure returns to its normal value, valve 9 closes automatically. [0084] Inlet filter 10. [0085] Metallic screen (AISI 316) to prevent solid particles from entering the circuit that could cause damage to a solenoid valve 13 arranged downstream, or to the patient. The screen pitch is 40 microns. [0086] Inlet filter housing 11. [0087] Housing for inlet filter 10. It has inlet and outlet connections for CO.sub.2. [0088] Manifold 12. [0089] It supports a solenoid valve 13 and allows connecting its inlet and outlet ports. [0090] Solenoid valve 13. [0091] A solenoid valve 13 is used to control the opening of the CO.sub.2 diffusion circuit in the patient's eye. It is a 2-way, 2-position solenoid valve of the bistable type. It incorporates a 12-aluminum manifold. The actuation of the solenoid valve 13 is controlled by 2 signals generated by a microprocessor 27 and subsequently driven by a solenoid valve driver 29, both arranged on an electronic control board 18, which will be described later. [0092] Outlet filter 14. [0093] Metal screen (AISI 316) to prevent solid particles from entering the circuit that could cause obstruction in a flow rate 17 regulation means arranged downstream or reaching the patient. The screen pitch is 40 microns. [0094] Outlet filter housing 15. [0095] Housing for outlet filter 14. It has CO.sub.2 inlet and outlet connections. [0096] Outlet safety valve 16. [0097] Mechanical pressure relief valve. Protects the circuit from accidental pressures higher than the set pressure set on the pressure regulation means 8, here a pressure regulator. The CO.sub.2 is released to the outside through an opening in the housing 2 of the device 1. The valve 16 is regulated by means of a spring set at pressure adequate. Once the pressure returns to its normal value, valve 16 closes automatically. [0098] Flow rate 17 regulation means [0099] In this example, an outlet flow restrictor is used, which comprises the nozzle 3 or calibrated CO.sub.2 dispensing needle (in diameter and length) that allows, for a given pressure, to maintain the CO.sub.2 outlet flow at a value predefined. [0100] Electronic control board 18. [0101] Electronic board 18 that incorporates all the necessary components to control the device 1, basically: [0102] On/off push button 19 of device 1 [0103] Li-Ion battery 24 and its charging circuit 28 [0104] Microprocessor 27 [0105] Inputs: digital trigger button 20, analog input pressure sensor 25 and output pressure sensor 26. [0106] Outputs: Actuation of solenoid valve 13 through solenoid valve driver 29. [0107] Light indicators 21, 22 and 23. [0108] On/off button 19. [0109] If the device is off, pressing it for a while turns the device on. [0110] If the device is on, pressing it for a while turns the device off. [0111] This button also allows you to leave the device in a very low consumption standby or “sleep” state, either by pressing it for a while or after a predefined period of inactivity. [0112] Trip button 20. [0113] Pushbutton which, when activated by the user (by means of trigger 4), generates a digital input signal to the electronic control board 18. This signal is used by the microprocessor 27 to start the test, if all the necessary conditions are met, and therefore generate the CO.sub.2 puff, as will be explained later. [0114] Power indicator 21. [0115] LED type indicator (Green). [0116] On in continuous mode, indicates that device 1 is on. [0117] Lit in oscillating mode, indicates low battery charge level 24. [0118] Battery charge status indicator 22 24. [0119] LED type indicator (Blue) that allows differentiating the different states of the battery charging process 24: charging and charged. [0120] Trip/Pressure Indicator 23. [0121] Two-color LED indicator (Green/Red). [0122] In green color, it turns on continuously during the CO.sub.2 shooting period. [0123] In green, it lights up in oscillating mode to indicate low pressure in the CO.sub.2 circuit. [0124] In red color, it lights in continuous mode to indicate obstruction in the CO.sub.2 circuit. [0125] In red color, it lights up in oscillating mode to indicate excessive pressure in the CO.sub.2 circuit. [0126] Battery 24. [0127] 24 rechargeable lithium-ion battery, with a nominal voltage of 3.7V and an approximate capacity of 165 mA/hour. In this example, the battery is integrated so it is not accessible to the user. [0128] Inlet pressure sensor 25. [0129] Differential type pressure sensor 25 and analog output. It measures the pressure P1 at the outlet of the pressure regulation means 8 so that the microprocessor 27 can verify that it is adequate. It is used to detect empty cartridge 7, excessive regulation means 8 outlet pressure or CO.sub.2 circuit clogging. [0130] Outlet pressure sensor 26. [0131] Pressure sensor 26 of differential type and analog output. It measures the pressure P2 at the inlet to the CO.sub.2 outlet flow restrictor so that the microprocessor 27 can verify that it is adequate. It is used for the detection of excessive pressure in the flow restrictor or obstruction of the CO.sub.2 circuit. [0132] Microprocessor 27. [0133] It processes the status information of the device and, based on the inputs, manages the status of the outputs. It includes the necessary control software program for its operation that will manage the input signals (digital and analog) and the output signals (actuation of the solenoid valve and LED indicators). [0134] Battery charging circuit 28. [0135] Monitors the battery charge 24. Monitors the operation of the battery charge status indicator 22. [0136] Driver 29 of solenoid valve. [0137] It conditions the opening and closing signals of the solenoid valve 13 (generated in the microprocessor 27) to adapt them to the requirements of the solenoid valve 13. [0138] USB 30 input for battery charging. [0139] Micro USB connector, compatible with standard USB chargers. Just use the power pins. Data pins do not connect. Alternatively, another type of connector could be used such as a Jack connector. [0140] External charger 31. [0141] Standard charger for devices with Micro USB charging input, or alternatively with charging input for a Jack connector. [0142] Input voltage: 110/220 V; 50/60 Hz. [0143] Output voltage: continuous=5 V.

[0144] The handheld device 1 is therefore powered by batteries 24 and is normally used without connection to the electrical network. In case of low battery level, the device 1 can also be used while connected to the mains to recharge batteries 24. Recharging the batteries 24 will be carried out by using the external charger 31 connected to the mains power supply—low voltage (110/220 V; 50/60 Hz).

[0145] Likewise, the housing 2 of the device 1 comprises a removable portion, located in the area of the handle 2a, provided with an internal cavity for the placement of a CO.sub.2 cartridge that can be coupled to the pressure regulation means 8 by means of mutual coupling means, such as threading means, which guarantee the sealing of the cartridge in its position of use.

[0146] Next, with reference to FIGS. 6 and 7, the operation of the device 1 of the invention is briefly described.

[0147] The CO.sub.2 cartridge 7 supplies the pressure regulation means 8, here a pressure regulator, with a flow of CO.sub.2 at high pressure (between 50 bar when the cartridge is completely full and 0 bar when it is empty). To do this, the cartridge 7 should be screwed into the threaded inlet port of the pressure regulator. This should be done as quickly as possible to avoid excessive gas loss.

[0148] The pressure regulator will adjust its outlet pressure according to the set point that has been set in the manufacture of the device 1. This pressure will be greater than or equal to 1.2 bar (17.4 psia).

[0149] The output of the pressure regulator is derived by means of a tube in three connections: [0150] To the inlet safety valve 9 so that, if the inlet pressure exceeds the maximum safety established, the gas would escape directly to the outside, avoiding possible damage to the circuit, the user or the patient. [0151] To the inlet pressure sensor 25 located on the electronic control board 18, so that the microprocessor 27 can signal possible failures in the gas circuit (low pressure, excessively high pressure or blockage of the circuit) by means of the corresponding indicator 23. [0152] To the housing 11 of the inlet filter 10 of the CO.sub.2 circuit. [0153] Once the CO.sub.2 flow passes through the casing 11 of the inlet filter 10, the outlet of the casing 11 of the inlet filter 10 is connected by tube to the inlet of the manifold 12 of the solenoid valve 13.

[0154] The outlet of the manifold 12 is connected by tubing to the inlet of the housing 15 of the outlet filter 14.

[0155] The outlet of the casing 15 of the outlet filter 14 is derived in three connections by tube: [0156] To the outlet safety valve 16 so that, if the inlet pressure exceeds the maximum safety established for the outlet, the gas would escape directly to the outside, avoiding possible damage to the circuit, the user or the patient. [0157] To the outlet pressure sensor 26 located on the electronic control board 18. The objective is to check that the outlet pressure is adequate to achieve the desired CO.sub.2 flow rate and that the microprocessor 27 can signal possible failures in the gas circuit (low pressure, excessively high or blockage of the circuit) by means of the corresponding indicator 23. [0158] To the outlet flow rate 17 regulation means, here the flow restrictor, for the emission of CO.sub.2 to the outside with the pre-established flow.

[0159] In the example described, the device 1 can be in three normal states (standby; on; and shooting), in two warning states (low pressure on, and obstruction on) and in an alarm and blocking state (excessive pressure). Each of these states is briefly described below: [0160] Standby state: LEDs 21,22,23 off and non-essential peripherals power supply disabled; only the power supply to the microprocessor 27 is active, but it remains in a “sleep” state, with its clock and peripherals deactivated. It is possible to exit of this state (going to the “on” state) by pressing the on/off button 19 for a sufficient time (about 2 seconds). [0161] On state: System power supply is fully activated and with microprocessor 27 and its internal oscillator running. [0162] Shooting state: This state is accessed by activating trigger 4 under the appropriate operating conditions (appropriate battery level for correct operation and input pressure P1 between predetermined upper and lower limits of the set point). [0163] Low pressure on state (warning): This status is accessed when detecting a low inlet pressure problem P1 in the CO.sub.2 circuit. [0164] Obstruction-on status (warning): This status is accessed when detecting an obstruction problem in the CO.sub.2 circuit (detected during the shooting state). [0165] Excessive pressure state (alarm and blocking): This status is accessed when detecting an inlet pressure P1 of CO.sub.2 flow higher than the maximum allowed. This problem can be detected at any time while the device is not in sleep state.

[0166] A second preferred embodiment of the invention is shown in FIGS. 8 and 9 illustrating a fixed device 1′ of essentially horizontal configuration, fixedly attachable to the instrument holding bar of a conventional ophthalmic examination table (not shown), as per example a slit lamp. In this way, this fixed device 1′ makes it possible to apply the CO.sub.2 puff on the patient's eye when his head is kept in a fixed position thanks to the frontal support element and the chin rest provided by such examination tables. The same reference numerals have been used to identify those elements common to the handheld portable device 1 of the first embodiment.

[0167] Likewise, the trigger of this fixed device 1′ comprises remote actuation means (not shown) separate from the casing 2, such as an infrared remote control or an actuation pedal, in order to avoid any unwanted movement on the housing 2 when the user presses the trigger to generate the CO.sub.2 puff.

[0168] As mentioned above, the conventional filter paper strips used in the Schirmer test have a length of 30 mm indicated on a graduated scale printed on their surface. The inventors of the present patent application have found that, in some cases, said strips of conventional paper are too short when the reflex secretion with CO.sub.2 is evoked by using the device of the invention, since the area moistened by the tear reaches the distal end of the strip.

[0169] For this reason, the invention also provides for a set of improved measuring strips 40 for the performance of the Schirmer test, especially suitable for carrying out the measurement of the maximum reflex tear production generated by the device 1,1′ of the invention. For this purpose, some strips 40 of absorbent paper are available, millimeter-sized of greater length and less width than those existing in the market for the measurement of basal tear secretion, in order to avoid saturation when there is a very abundant tear.

[0170] In FIG. 10 an improved strip 40 according to the invention is shown by way of example, which is formed by a strip 40 of filter paper (for example, Whatman® No. 41) with a width of approximately between 5 and 10 mm and with a total length of approximately 50 mm, the proximal end of which intended to enter the space between the bulbar conjunctiva and the eyelid has a tongue-like shape 41 with rounded edges to eliminate sharp angles and thus avoid irritation. Furthermore, said strips 40 are sterilized with ethylene oxide and the end of the tab 41 contains a dried solution of an ocular anesthetic.

[0171] FIG. 11 shows the effect of CO.sub.2 stimulation with the device on the tear rate of healthy subjects. Individual values of BTR (black dots) and STR (white dots) of each patient are connected by an arrow and ordered sequentially by their BTR magnitude. Positive and negative values of Tearing reserve (Tr) have been wrapped in red and blue respectively, to emphasize the increased incidence of negative tear reserve values among subjects with higher BTR values.

[0172] FIG. 12. Healthy subjects ordered according to the magnitude of their positive tearing reserve (Tr). Subjects with BTR<18 mm (red arrows) or 18 mm (green arrows) have been plotted apart. Subjects with zero or negative Tr values have been excluded.

[0173] FIG. 13 shows the differences in STR within the population of healthy subjects. Healthy subjects with a basal tear Schirmer value below or equal to 10 mm maintain a positive response to maximal reflex stimulation (light red box). Healthy subjects with BTR values over 10 mm segregate in two distinct groups, those in which stimulation does not augment or decrease tearing (blue box) or keep a large tearing reserve (red box). STR values of subjects with BTR>10 mm (+) were different from those with BTR<10 mm (Kruskal Wallis, Dunn's method, p<0.05).

[0174] FIG. 14 shows the effect of CO.sub.2 stimulation with the CO.sub.2 stimulation device in subclinical patients. As in FIG. 11, Individual values of BTR (black circles) and STR (white circles) of each patient are connected by an arrow, and ordered sequentially by BTR magnitude. Positive and negative values of tearing reserve have been wrapped in red and blue respectively.

[0175] FIG. 15 shows the response curve to CO.sub.2 stimulation in the group of Sjögren syndrome patients. Data have been represented as in FIG. 11. Individual values of BTR (black squares) and STR (white squares) of each patient are connected by an arrow and ordered sequentially by BTR magnitude. Positive and negative values of tearing reserve have been wrapped in red and blue respectively. FIG. 16 is a comparison of the mean values of BTR (black) and STR (gray) in the groups of healthy subjects, subclinical DED patients and SS patients *p<0.05 Mann Whitney test.

EXAMPLES

[0176] The inventors evaluated the efficacy and reproducibility of the device to stimulate tear secretion, measuring in human subjects of both sexes the tear secretion volume evoked by maximal reflex stimulation of the lacrimal glands obtained by stimulation of corneal nociceptors and cold thermoreceptors of the ocular surface with the device described in the present invention in subjects of both sexes, healthy and with eye dryness at two levels of severity: Subclinical and with Sjögren's Syndrome (SS) diagnosed using basal Schirmer's test values, tear meniscus size; tear film breakdown time (TBUT), corneal staining level graded with the Oxford scale and Mcmonnies symptomatology questionnaire. Two groups of patients were used: [0177] Group 1 (control), comprised healthy and asymptomatic volunteers of both sexes, aged between 20 and 69 years (n=53) with Schirmer test>8 mm in 3 min., TBUT>7 s. and 0 degrees of superficial punctate keratitis (SPK). [0178] Group 2 (ophthalmological patients) included 46 subjects of both sexes, aged between 20 and 69 years, who in turn were divided into:

[0179] A. Subclinical DED patients, with Schirmer test <10 mm in 3 min and the TBUT<7 s (n=13).

[0180] B. Sjögren's Syndrome (SS) patients, diagnosed of dry eye associated with primary or secondary SS, according to the standard criteria established for the identification of this pathology (n=30).

[0181] Schirmer test values were obtained under basal conditions (basal tear rate, BTR) in one eye and after 10 min in the contralateral eye immediately after application of a 4 s CO.sub.2 pulse with the device of the present invention (stimulated tear rate STR), in control subjects and in patients with subclinical asymptomatic low BTR and with severe dry eye disease (SS).

[0182] Immediately before applying the Schirmer paper strip, 3 μl of 2% lidocaine was instilled with a micropipette to the flap the strip in contact with the conjunctiva in order to locally anesthetize only this area palpebral mucosa, thus avoiding mechanical irritation of the conjunctiva. BTR was measured for 3 min under resting conditions.

[0183] The reflex tear secretion evoked by CO.sub.2 stimulation was performed 10 min later in the eye contralateral to that of the control measurement. For this, the eye socket was applied on the orbit and the patient was asked to look directly to the outflow orifice. Then a 99% CO.sub.2 pulse was applied. Immediately afterwards, a Schirmer strip with its tab impregnated with 3p1 of 2% lidocaine was placed on the lower lid of the stimulated eye, maintaining it for 3 min and to obtain the STR. Noteworthy, in the usual practice of the Schirmer test under anesthesia, 10 μl of 0.4% oxybuprocaine is instilled in the conjunctival sac and 5 minutes are waited before performing the Schirmer test.

[0184] CO.sub.2 stimulation evoked a significant tear flow increase. The average STR of the positive responders was 20.8±1.3 mm, which represents a 46.5% increase of their mean BTR value (14.2±1.1 mm (p<0.001, Wilcoxon test). No statistical differences of BTR and STR values were found between male and female healthy subjects (p=0.981 and p=0.306 respectively, Mann Whitney test).

[0185] In FIG. 12, the individual values of BTR and STR of all members of healthy subjects' group (n=46), have been ordered according to their BTR value. This representation evidences the high incidence (72.4% of the total) of positive responses (red arrows) to the stimulus and also that the number of subjects in which STR values evoked by CO.sub.2 do not overpass their BTR was low. The amplitude of the STR value was rather variable, ranging from 5 mm to a highest peak value near 40 mm. FIG. 12 also shows that null or negative responsiveness to the stimulus was not observed in any of the healthy subjects whose pre-stimulus BTR value was below 10 mm, but tend to appear with increasing frequency and with larger negative values among subjects with higher pre-stimulus BTR level.

[0186] In each healthy subject, we measured the difference between BTR and STR, a parameter that we named Tearing reserve (Tr) and is usually positive in healthy subjects (red arrows, FIG. 12). All subjects with low pre-stimulus BTR values, between 7 and 10 mm (n=16) responded positively to the stimulus, with a mean Tr of +6.8±0.9 mm. Among subjects showing BTR levels over 10 mm (n=30), two-thirds were still able to augment tearing with CO.sub.2 stimulation, with a similar mean Tr=+7.1±0.8 mm while the rest exhibited a negative Tr (blue arrows, FIG. 12). Noteworthy, within the group of fourteen subjects showing a BTR≥18 mm, eleven still produced vigorous tearing in response to CO.sub.2 stimulation, reaching a mean Tr value of +6.6±1.0 mm (n=11) (FIG. 13, green arrows). FIG. 13 highlights the remarkable capacity of this subgroup of subjects of producing large total tear volumes. There, BTR and STR values of positively responding healthy subjects have been ordered according to the magnitude of their Tr value but plotting separately subjects with BTR value below 18 mm (red) or over 18 mm (green). The graph shows that a subgroup of subjects exhibiting a high BTR still maintain the capacity to respond with a marked increase of their tear secretion (i.e. of keeping a normal tearing reserve value) thus being able to evoke higher final STR values in comparison with subjects with a lower BTR. Accordingly, the mean value of STR (30.0±2.0 mm) in this subgroup of strongly responding subjects with an already high BTR (≥18 mm) is significantly higher than in subjects responding positively to the CO.sub.2 stimulation with a BTR<18 mm (17.0±0.9 mm; p<0.001, Mann Whitney test)

[0187] In FIG. 14 we represented the mean STR of all healthy subjects. Those with a BTR≤10 mm (34.8% of the total, light red box), responded positively to CO.sub.2 stimulation. Subjects with higher BTR values could be subdivided between those unable to further increase tearing or even exhibiting a lower tearing rate when stimulated (17.4% of the total, blue box), and the group maintaining the capacity to increase tearing under stimulation (47.8% of the total, red box).

[0188] Altogether, our data indicate that individual differences in total tear secretion capacity in healthy subjects are ample and that subjects considered normal by their BTR value may actually be close to their maximal tearing capacity.

[0189] The group of individuals subclinical DEP patient was characterized by a BTR<7 mm and/or a TBUT<7 s, low tear meniscus height and a moderate level of corneo-conjunctival epitheliopathy clinically suggestive of moderate DED, but without subjective signs of the disease according to their scores in the McMonnies questionnaire.

[0190] The change of tearing rate evoked by CO.sub.2 stimulation in 12 patients belonging to this non-symptomatic group is shown in FIG. 14. The profile of their response curve is qualitatively very similar to the one obtained in healthy subjects (compare with FIG. 11). However, in contrast with them, in subclinical DED patients, the incidence of negative responses or no response to CO.sub.2 stimulation was higher, already appearing in subjects with low BTR values. Moreover, only in two of the subclinical patients the value of peak STR overpasses 16 mm. Still, low tear secretion under basal conditions in the patients with BTR below 7 mm, apparently does not totally compromise the capacity of their lacrimal glands to increase secretion under nociceptive stimulation. In fact, the average tearing reserve (Tr) value of the group was +6.1±1 mm, n=7, only slightly lower than the equivalent Tr value in healthy subjects with a BTR below 10 mm (compare FIGS. 11 and 14). However, more than half of the subclinical DED patients were unable to reach a peak tear volume of 10 mm under CO.sub.2 stimulation. Statistical analysis showed no significant correlation between BTR and STR in subclinical DED subjects (p=0.6, Pearson correlation coefficient=−0.168), but showed a negative correlation between BTR and Tr (p=0.024, Pearson correlation coefficient=−0.642).

[0191] The group of SS-DED patients was composed of 30 patients derived to Ophthalmology by the Service of Rheumatology and diagnosed as primary SS (9 patients) or secondary SS (21 patients).

[0192] The individual responses to CO.sub.2 of all the members of the SS group are shown in FIG. 15. There, patients have been ordered as a function of their BTR value as in control and subclinical groups. Up to BTR values ≤7 mm, most patients (17/21) exhibited a positive albeit modest tearing response to CO.sub.2 stimulation (mean rise: +3.1±0.6 mm, n=17). For BTR>7 mm only three out of 9 patients increased their Schirmer test score in 1-3 mm, while the rest remained unchanged or decreased. Taken together, these data indicate that the Tr of SS patients is in general very low, and that the BTR appears to be at or near maximal level already under basal conditions in about 50% of the patients.

[0193] FIG. 16 summarizes the mean values of BTR and STR obtained in healthy, subclinical DED subjects and SS-DED patients, confirming that SS-DED patients exhibit significantly lower tear secretion under basal conditions, but also showing that in these patients, despite the functional insufficiency of their tear glands, a capacity to increase tear flow under maximal reflex stimulation still remains. A similar secretion pattern is also observed in subclinical patients, in which slightly higher values of BTR and STR apparently prevent the apparition of open DED symptoms.

[0194] We report here the results obtained with a new ophthalmic instrument that generates a CO.sub.2-evoked maximal stimulation of the sensory nerve terminals innervating the corneal surface, thereby evoking a strong reflex activation of tear gland's secretion and a rise in the aqueous tear flow. This sudden increase of the tear volume possibly represents the maximal acute secretory capacity of the gland. Comparison of the results obtained with this procedure between healthy subjects and patients diagnosed of DED, evidence that the elevation of tear flow over its basal levels evoked by CO.sub.2 stimulation was very low in Sjögren syndrome patients displaying defined DED ocular signs and symptoms, but also in patients showing moderate signs of DED such as abnormal tear film stability and volume, and discrete corneal epithelium damage, but without complaining of subjective symptoms of DED. Thus, measurement of maximal reflex tear gland secretion with this simple procedure may provide useful information about the functional status of patient's tear glands and their capacity to prevent the development of ocular surface dryness. It may be useful also to follow and predict an evolution towards DED in subjects with a low BTR but without symptoms of the disease. Almost all of them were unable to increase their basal tearing rate under stimulation, and the STR of those responding positively did never overpass the mean value of BTR exhibited by healthy subjects. The response curve closely resembles the one of the SS patients, thus reinforcing the tenet that these are probably patients in a masked, early stage of lacrimal gland insufficiency. Clinically, SS patients' basal tearing levels are commonly used as an important functional sign of the magnitude of lacrimal gland damage produced by an autoimmune disorder Our data indicate that in contrast with healthy subjects, most SS patients have a maximal secretory capacity moving in a narrow range away from the BTR and rarely overpassing 12 mm. A corollary of this observation is that therapeutic procedures aimed at increasing the tearing reserve of SS patients to enhance their low basal tearing should take into consideration the actual range of potential tear volume increase still available for these patients.

[0195] Altogether, our observations support the tenet that maximal tear flow values evoked with reflex chemical stimulation of corneal nerves reflect with reasonable fidelity the functional status of the tear secretory glands. Moreover, values of maximal secretory capacity and tearing reserve may be useful to predict the functional capability of lacrimal glands to respond to environmental challenges and to react against a variety of systemic or eye disorders that are accompanied by ocular surface infection and/or inflammation, wherein insufficient tear flow contributes to aggravate the altered condition of the eye surface. It is well known that reflex compensatory tearing in response to ocular surface stress following surgery or under prolonged contact lens wearing is important to prevent injury of the corneal epithelium and its nerves and the accompanying inflammation and unpleasant dryness and pain sensations. Knowledge of lacrimal gland secretory condition using controlled reflex stimulation of the eye surface in prospective patients of photorefractive surgery or contact lens users may help eye care professionals to adopt informed decisions about the convenience and potential risks of these procedures in some patients before applying them to improve the refractive state of the eye.